Neurotech InternationalASX:NTI -7.14% PB Ratio is 2.60 as of Jun. 26, 2026, which is 26% below its 10-year median of 3.50. The stock has 1 warning sign investors should review. Among 1,232 Biotechnology companies, Neurotech International ranks better than 50.16% on this metric.
The historical rank and industry rank for Neurotech International's PB Ratio or its related term are showing as below:
ASX:NTI'
s PB Ratio Range Over the Past 10 Years
Min: 0.16 Med: 3.5 Max: 12.5
Current: 2.6
During the past 9 years, Neurotech International's highest PB Ratio was 12.50. The lowest was 0.16. And the median was 3.50.
ASX:NTI's PB Ratio is ranked better than 50.16% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs ASX:NTI: 2.60
During the past 12 months, Neurotech International's average Book Value Per Share Growth Rate was -16.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 14.50% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Neurotech International was 26.00% per year. The lowest was -43.90% per year. And the median was 7.25% per year.
Back to Basics: PB Ratio
Neurotech International (ASX:NTI) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Neurotech International's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurotech International PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neurotech International's PB Ratio distribution charts can be found below:
* The bar in red indicates where Neurotech International's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Neurotech International (ASX:NTI) has a PB Ratio of 2.60 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Neurotech International and its competitors. This is 26% below median its historical median of 3.50. Over the past decade, Neurotech International's PB Ratio has ranged from 0.16 to 12.50. According to the industry distribution chart, Neurotech International ranks #614 out of 1232 companies in the Biotechnology industry, placing it in the top 49.8%.
Is Neurotech International's PB Ratio too high?
Neurotech International's current PB Ratio of 2.60 is 26% below median its 10-year median of 3.50. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 12.50. The Biotechnology industry median PB Ratio is 2.80. Neurotech International's value of 2.60 is 7.1% below this industry median. Based on the distribution chart, Neurotech International ranks #614 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint.
How does Neurotech International's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neurotech International ranks #614 out of 1232 companies for PB Ratio. This puts Neurotech International in the upper half of its industry. The industry median PB Ratio is 2.80. Neurotech International's value of 2.60 is 7.1% below this benchmark. Historically, Neurotech International's own PB Ratio has ranged from 0.16 to 12.50 over the past decade. While the company's 10-year median is 3.50 vs. the industry median of 2.80, Neurotech International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurotech International's current PB Ratio of 2.60 is 7.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Neurotech International and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurotech International's current PB Ratio is 2.60, which is 26% below median its own 10-year median of 3.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (ASX:NTI) has a current PB Ratio of 2.60. The current PB Ratio is 2.60, which is 26% below median its 10-year median of 3.50 and 7.1% below the Biotechnology industry median of 2.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Neurotech International (ASX:NTI), the current PB Ratio is 2.60 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NTI has been successfully added to your 